Group 1: Company Performance - In Q1 2025, the revenue from soft elastic noodles exceeded 20 million yuan, with a year-on-year growth of over 70% [3] - The net profit for Q1 2025 increased by over 100% year-on-year, attributed to product structure optimization and cost control [4] - The company experienced a 13.54% year-on-year decline in revenue, yet achieved significant net profit growth [5] Group 2: Product Development and Market Strategy - The company plans to gradually release production capacity at the Jiaxing base, focusing on high-end noodles and instant products [2] - New product launches will include a refined range of mixed grain and customized series to meet market demands [3] - The company aims to expand its market presence in wholesale, catering, and snack retail channels in 2025 [5] Group 3: Consumer Insights and Marketing - Approximately 70% of the company's end consumers are female, with traditional noodle products primarily consumed by individuals aged 40 to 70 [4] - Targeted marketing efforts for the "Wheat Road" brand focus on young male consumers through precise online advertising [4] - The company has not yet collaborated with gaming companies but is open to exploring various promotional strategies [4] Group 4: Financial Management and Investor Relations - The company is committed to enhancing shareholder value through cash dividends, information disclosure, and investor relations management [3] - Suggestions for physical product dividends to shareholders will be communicated to management for consideration [3] - The company maintains a strong capacity to manage risks associated with raw material price fluctuations through diversified wheat procurement strategies [5]

毛利率有所提升，25Q1 盈利能力进一步增强。毛利率方面，2024 全年/24Q4/25Q1 公司毛利率分别为 28.36%/25.99%/29.50%，25Q1 同比+0.12pcts，环比+3.51pcts。主要系原奶价格下滑叠加产品结构优 化，公司毛利率进一步提升。 费用端，2024 全年/24Q4/25Q1 销售费用率分别为15.56%/14.68%/ 17.01%，25Q1 同比-0.07pcts，环比 +2.33pcts。2024 全年/24Q4/25Q1 管理费用率分别为3.57%/1.22%/3.54%，25Q1 同比-1.57pcts，环比 +2.31pcts。综合来看，2024全年/24Q4/25Q1 公司归母净利率分别为5.04%/2.54%/5.08%，25Q1 同比 +1.64pcts，环比+2.53pcts，盈利能力有所增强。子公司中，四川乳业/昆明雪兰/寰美乳业/青岛琴牌2024 年净利润率分别为7.13%/4.60%/6.37%/6.77%，同比-1.21/-0.23/-2.32/+1.35pcts，主要系部分子公司以常 温业务为主，受终端竞争加剧影响，利润端短期承压。25Q1 ...

2025 年 5 月 6 日 公司研究 低温业务增势良好，盈利能力持续提升 ——新乳业（002946.SZ）2024 年报及 2025 年一季报点评 要点 事件：新乳业发布 2024 年年报和 2025 年一季报，2024 全年实现营业收入 106.65 亿元，同比-2.93%；归母净利润 5.38 亿元，同比+24.80%；扣非归母净 利润 5.79 亿元，同比+24.47%。其中，24Q4 单季度实现营业收入 25.16 亿元， 同比-9.94%；归母净利润 0.64 亿元，同比+28.08%；扣非归母净利润 0.72 亿元， 同比-2.25%。25Q1 实现营业收入 26.25 亿元，同比+0.42%；归母净利润 1.33 亿元，同比+48.46%；扣非归母净利润 1.41 亿元，同比+40.35%。 低温品类持续向好，电商渠道增长积极。1）分产品看，2024 年液态奶/奶粉/ 其他产品分别实现营收 98.36/0.71/7.58 亿元，同比+0.83%/-9.63%/ -34.27%。 其中低温鲜奶和低温酸奶收入同比实现中高个位数增长，高端鲜奶及低温调制乳 品类收入同比实现双位数增长。公司持续推进新品 ...

Investment Rating - The report assigns a "Buy" rating to the company, with a target price of 30.24 yuan for the next six months, indicating an expected price increase of over 15% compared to the market benchmark [5]. Core Insights - The company experienced a decline in revenue and net profit in 2024, with total revenue of 3.048 billion yuan, down 6.61% year-on-year, and a net profit of 719 million yuan, down 11.15% year-on-year. However, the first quarter of 2025 showed signs of recovery with revenue of 737 million yuan, down 8.11% year-on-year, but net profit increased by 7.03% to 181 million yuan [1][2]. - The pre-mixed cocktail segment faced challenges, with revenue of 2.677 billion yuan in 2024, a decrease of 7.17% year-on-year. Despite this, the gross margin improved by 2.42% due to product mix optimization and lower raw material costs. The edible flavoring business grew steadily, achieving revenue of 337 million yuan, up 6.30% year-on-year [2]. - The company is actively expanding its liquor business, launching new whiskey products and targeting a broader market. The whiskey segment is expected to exceed expectations, with projected revenues of 3.615 billion yuan in 2025, 4.148 billion yuan in 2026, and 4.792 billion yuan in 2027 [3]. Financial Summary - The company reported a total revenue of 3.048 billion yuan for 2024, with projections of 3.615 billion yuan for 2025, 4.148 billion yuan for 2026, and 4.792 billion yuan for 2027, indicating a recovery trajectory [4][10]. - The net profit for 2024 was 719 million yuan, with forecasts of 882 million yuan for 2025, 1.045 billion yuan for 2026, and 1.211 billion yuan for 2027, reflecting a positive growth outlook [4][10]. - The earnings per share (EPS) are projected to be 0.84 yuan in 2025, 1.00 yuan in 2026, and 1.15 yuan in 2027, with a price-to-earnings (P/E) ratio of 36 times for 2025 [4][10].

Investment Rating - The report does not provide a specific investment rating for the company Zhejiang Natural (605080) [1] Core Views - The company reported a revenue of 1.002 billion yuan in 2024, representing a year-on-year increase of 21.8%, and a net profit attributable to shareholders of 185 million yuan, up 41.7% year-on-year [1] - The company is expected to optimize its product structure and increase market share, leading to steady revenue growth, while overseas bases are accelerating their development [1][2] - The company’s overseas bases are entering a harvest period, with limited impact from tariffs, and profitability is expected to improve in 2025 [3] Summary by Sections Financial Performance - In Q1 2025, the company achieved a revenue of 357 million yuan, a year-on-year increase of 30.4%, and a net profit of 96 million yuan, up 148.3% year-on-year [1] - The company’s gross profit margin in Q1 2025 was 38.8%, an increase of 0.5 percentage points year-on-year, with a net profit margin of 26.9%, up 12.8 percentage points year-on-year [3] Product Structure and Growth - The revenue from air beds, bags, pillows, and other businesses in 2024 was 586 million, 204 million, 70 million, and 134 million yuan respectively, with year-on-year growth rates of 13.9%, 30.9%, 15.7%, and 48.0% [2] - The company is expanding its customer base in the new energy vehicle market and enhancing its product offerings in the camping sector [2] Overseas Expansion - The company has three main overseas bases in Vietnam, Cambodia, and Morocco, which are all developing simultaneously and are expected to enhance the company's global supply chain share [3] - The profitability of these overseas bases is anticipated to recover in 2025, reaching a stable level by 2026 [3] Cash Flow and Operational Efficiency - The operating cash flow for Q1 2025 was 13 million yuan, with inventory turnover days at 112.08 days, a decrease of 5.91 days year-on-year [4] - The company is managing expenses effectively, with a total expense ratio of 7.98% in Q1 2025, down 4.0 percentage points year-on-year [3]

Investment Rating - The report does not provide a specific investment rating for the company Zhejiang Natural (605080) [1] Core Views - The company reported a revenue of 1.002 billion yuan in 2024, representing a year-on-year increase of 21.8%, and a net profit attributable to shareholders of 185 million yuan, up 41.7% year-on-year [1] - The company is expected to optimize its product structure and increase market share, leading to steady revenue growth, while overseas bases are accelerating their development [1][2] - The company’s overseas bases are entering a harvest period, with limited impact from tariffs, and profitability is expected to recover in 2025 [3] Financial Performance Summary - In Q1 2025, the company achieved a revenue of 357 million yuan, a year-on-year increase of 30.4%, and a net profit of 96 million yuan, up 148.3% year-on-year [1] - The company’s gross margin in Q1 2025 was 38.8%, an increase of 0.5 percentage points year-on-year, while the net profit margin was 26.9%, up 12.8 percentage points year-on-year [3] - The company’s operating cash flow for Q1 2025 was 13 million yuan, a decrease of 21 million yuan year-on-year [4] Product Structure and Market Development - The revenue from air beds, bags, pillows, and other businesses in 2024 was 586 million, 204 million, 70 million, and 134 million yuan respectively, with year-on-year growth rates of 13.9%, 30.9%, 15.7%, and 48.0% [2] - The company is expanding its overseas bases, particularly in Vietnam and Cambodia, which are expected to enhance production efficiency and profitability [3][2] Profitability Forecast - The company’s net profit attributable to shareholders is projected to be 290 million, 380 million, and 490 million yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 12.8X, 9.6X, and 7.5X [4]

| [Table_BaseData] 收盘价（元） | 33.50 | | --- | --- | | 近 12 个月最高/最低（元） | 47.50/28.10 | | 总股本（百万股） | 209 | | 流通股本（百万股） | 194 | | 流通股比例（%） | 92.90 | | 总市值（亿元） | 70 | | 流通市值（亿元） | 65 | [公司价格与沪深 Table_Chart] 300 走势比较 可孚医疗（ [Table_StockNameRptType] 301087） 公司点评 产品丰富+渠道多元，收入增长持续稳健 | 投资评级：买入（维持） [Table_Rank] | | --- | | 报告日期： 2025-05-04 | -31% -16% -2% 13% 28% 5/24 8/24 11/24 2/25 可孚医疗 沪深300 [Table_Author] 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com 分析师：李婵 执业证书号：S0010523120002 邮箱：lichan@hazq.com [Table_CompanyRepo ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady revenue growth with a diverse product range and multiple sales channels, achieving a revenue of 2.983 billion yuan in 2024, a year-on-year increase of 4.53%, and a net profit of 312 million yuan, up 22.60% year-on-year [5][9] - The company focuses on core product categories and enhances R&D efficiency, launching over a hundred new products, including innovative solutions for chronic disease management [6] - The online sales channel generated 1.990 billion yuan in revenue, a growth of 8.94% year-on-year, while the offline channel saw a decline of 3.12% [7][8] Financial Performance Summary - In 2024, the company achieved a revenue of 2.983 billion yuan, with a net profit of 312 million yuan and a gross margin of 51.9% [11] - Revenue projections for 2025-2027 are 3.580 billion yuan, 4.333 billion yuan, and 5.236 billion yuan, with corresponding net profits of 414 million yuan, 504 million yuan, and 613 million yuan [9][11] - The expected EPS for 2025-2027 is 1.98 yuan, 2.41 yuan, and 2.93 yuan, with P/E ratios of 17x, 14x, and 11x respectively [9][11]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 45.89 CNY, based on a valuation of 149 billion CNY using the FCFF method [2][4][10]. Core Views - The company is experiencing weak sales performance, with a significant decline in revenue and net profit in 2024, attributed to a challenging consumption environment. The report anticipates a gradual recovery in 2025, contingent on macroeconomic factors [9][10]. - The company aims to optimize its product structure and deepen market operations, focusing on core markets and reducing inefficient SKUs by 50% [9][10]. Financial Forecasts - Revenue for 2024 is projected at 1.423 billion CNY, a decrease of 49.7% year-on-year, with a further decline expected in 2025 to 1.248 billion CNY [3][9]. - The net profit for 2024 is expected to be 0.1 billion CNY, down 97.7% year-on-year, with a recovery forecasted to 0.171 billion CNY in 2025 [3][9]. - The earnings per share (EPS) are projected to be 0.04 CNY in 2024, increasing to 0.53 CNY in 2025 and 0.62 CNY in 2026 [3][10]. Key Financial Metrics - The company reported a gross margin of 71.4% in 2024, down from 78.3% in 2023, and a net margin of 0.9%, a significant drop from 19.4% in the previous year [3][9]. - The total expenses ratio increased to 48.9% in 2024, reflecting a rise of 13.9 percentage points year-on-year, indicating higher operational costs [9][10]. - The company's cash flow remains robust, supporting its valuation despite the current challenges [10].

Core Viewpoint - The company reported significant declines in revenue and net profit for 2024 and Q1 2025, indicating a challenging market environment and weak sales performance across key product lines [1][2][3]. Financial Performance - In 2024, the company achieved revenue of 1.42 billion yuan, down 49.7% year-on-year, and a net profit of 10 million yuan, down 97.7% year-on-year [1]. - For Q4 2024, revenue was 230 million yuan, a decrease of 66.2%, with a net profit of -40 million yuan, reflecting a decline of 163.7% [1]. - In Q1 2025, revenue was 340 million yuan, down 30.3% year-on-year, and net profit was 30 million yuan, down 56.8% year-on-year [1]. - The overall gross margin for 2024 was 71.4%, a decrease of 7.0 percentage points, while the net profit margin was 0.9%, down 18.5 percentage points [2]. - The company’s expense ratio for the year was 48.9%, an increase of 13.9 percentage points, with specific increases in management, sales, and R&D expenses [2]. Product and Market Strategy - The company plans to focus on product structure optimization and deep market operations in 2025, aiming to enhance operational efficiency in core markets [3]. - A "2+2+2" strategic product system will be established, with plans to eliminate 50% of inefficient SKUs and optimize price distribution [3]. - Initial signs of improvement are noted with a 95% year-on-year increase in sales indicators, suggesting that reforms are beginning to take effect [3]. Future Outlook - The company has adjusted revenue and gross margin forecasts downward for 2025-2026 while increasing expense ratio expectations [3]. - Projected earnings per share for 2025-2027 are 0.53, 0.62, and 0.96 yuan, respectively, down from previous estimates [3]. - The company maintains a target equity value of 14.9 billion yuan, corresponding to a target price of 45.89 yuan, with a buy rating [3].